NAA Services for Anti-CENPF
Creative Biolabs has been focusing on NAA (natural autoantibodies) research for many years and has successfully constructed a series of innovative and diversified NAA platforms to provide professional services for our clients throughout the world. At present, we are able to provide a full range of anti-CENPF marker services for diseases diagnosis and therapeutic monitoring.
Background of Anti-CENPF
Centromere protein-F (CENPF), also known as P330 and mitosin, is an essential nuclear protein associated with the centromere kinetochore complex and plays a critical role in chromosome segregation during G2 and mitosis. It has a role in centromere/kinetochore maturation, chromosome alignment and segregation, regulation of the metaphase checkpoint, anaphase spindle stabilization, and cytokinesis. CENPF functions in a cell cycle manner, presents as a nuclear matrix protein during interphase then redistributes during early G2 of the cell cycle. Autoantibodies against CENPF protein have been demonstrated in patients with cancers or graft versus host disease. Up-regulation of CENPF expression has previously been detected in several solid tumors, with increased immunohistochemical expression of CENPF reported in breast, lung, ovarian and cervical cancer, non-Hodgkin lymphoma as well as squamous cell carcinoma of the esophagus, oral mucosa, and gingiva.
Fig.1 Farnesylation of CENPF is essential for the G2/M transition to maintain normal progression of the cell cycle.1
The Role of CENPF in Primary Liver Cancer
Hepatocellular carcinoma (HCC) is the fifth most common and the third most deadly type of liver cancers in the world. Amplification of the long arm of chromosome 1 (1q) is one of the most frequent genetic alterations in HCC. Therefore, the candidate oncogene, CENPF at 1q41 expressed in a cell cycle-dependent manner, was found frequently overexpressed in HCC as compared with non-tumor tissue. The expression of CENPF was remarkably increased in HCC, accompanying by venous invasion, advanced differentiation stage, and shorter overall survival. Both in vivo and in vitro functional studies found that silencing CENPF in HCC cells could significantly decrease the ability of the cells proliferation and colonies formation, and inhibit tumor formation in nude mice. CENPF knocking-down also resulted in the cell cycle arresting at G2/M checkpoint by down-regulating cell cycle proteins cdc2 and cyclin B1. CENPF overexpression may serve as a powerful prognostic marker for HCC and also a novel therapeutic target for the disease. Thus, anti-CENPF antibodies are useful tools in assisting HCC diagnosis.
What We Can Do About NAA?
With our high-end technologies, well-established platforms and experienced scientists, Creative Biolabs provides the largest and diversiform portfolio of NAA products and NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. All custom services or products are accepted and undertaken on a “best efforts” basis only. Our proven and optimized platforms can help you quickly get satisfactory results without repeated trials.
Please contact us for more information.
Reference
- Chen, Jiahao, et al. "Deciphering the Prognostic and Therapeutic Significance of Cell Cycle Regulator CENPF: A Potential Biomarker of Prognosis and Immune Microenvironment for Patients with Liposarcoma." International Journal of Molecular Sciences 24.8 (2023): 7010.
Related Services:
- NAA Services for Anti-Nucleophosmin (NPM) 1
- NAA Services for Anti-DNA Topoisomerase II
- NAA Services for Anti-Cytokeratin 8
- NAA Services for Anti-Nucleoside Diphosphate Kinase A
- NAA Services for Anti-α Fetoprotein (AFP)